Biotexcel Limited work in the area of Genomics and Diagnostics, organizing educational events such as conferences & workshops, providing technical and commercial consulting and organizing European wide research consortia.
The scientific theme for our events is based around Genomics, especially around the use of Next Generation Sequencing (NGS) in research and the clinic. The events help to foster a virtual ideas hub for genomic discovery scientists to network with clinicians.
We have strong scientific and commercial experience in the Genomics and Diagnostics industries and use this to provide advice to companies and hospital/university spin-outs.
Who We Are
Elisabetta founded Biotexcel Ltd in 2011 and started the business as a consulting firm that specialised in providing technical and commercial consulting to life science companies. Through the consulting business, Elisabetta struck up a collaboration with a client and this led to the first genomic event called NGS 2013 Oxford which was held as a partnership. This event then led to multiple collaborations across Europe with NHS and University genomic labs and resulted in a portfolio of several Europe-wide genomic events.
Ed who has a PhD in Genetics looks after strategic relationships with Biotexcel partners. These partnerships with NHS and University genomic groups has led to the evolution of our Genomic Medicine & NGS events in Europe. Ed is responsible for bringing together genomics based biomarker discovery, clinical and engineering groups to form research consortia which then apply for international funding for non-invasive diagnostic workflows. Ed uses his experience from these ventures to run workshops at all our genomic events. Ed also manages the consulting side of the business.
Dr Klaus Brusgaard who serves as a non-executive director at Biotexcel is an associate professor within the Clinical Genetics department of Odense University Hospital and Southern Danish University in Denmark and is also the co-founder of a successful genetic diagnosis company, Amplexa Genetics. Additionally, Klaus is external associate professor at Near East University, Cyprus. Klaus advises Biotexcel on scientific themes for our meetings and workshops and connects our business to high level collaborators around Europe where we operate. Klaus also provides strategic scientific and industry advice to Biotexcel that allow us to best direct our business towards the scientific academic community.
Steve trained in medicine and as a result of his direct experience with patients he is able to provide advice on patient perspectives in relation to genomic medicine and other areas of scientific interest to Biotexcel. Steve serves as a non-executive director and advises on many other aspects that relate to his multidisciplinary training and experience in areas ranging from general practice, pharmacology, psychiatry, Information and communication technologies, biotechnology and at the areas where these fields intersect.
Kevin Blighe who has a PhD has vast experience in Clinical Genomics & Bioinformatics. He has worked in many countries in Europe and North & South America and is also the founder of the Clinical Bioinformatics Company Ltd. Kevin has worked with Biotexcel Ltd in multiple capacities and is now a non-executive director, a scientific advisor as well as a key partner in our Research Consortia business.
Nikolai has the role of non-executive director as well as being partner in our Genomic Events business – he brings a wealth of experience and knowledge to us. Nikolai is Professor of Medical Biotechnology at University of Abertay, Dundee in addition to being the director of CMBCR and head of Cancer Systems biology. Nikolai is a distinguished academic as well as having worked in a senior level position in the Pharma industry, being head of department at Cyclacel. Currently Nikolai is honorary professor in eight universities in the UK, Bulgaria and China as well as the honorary consul general for Bulgaria in Scotland.
An excellent conference – to someone new to the area of circulating DNA, it provided a fantastic introduction to the research going on in real time.
Biotexcel focuses on the use of genomic technologies for improving human health.
Biotexcel is passionate about the use of genomic technologies to benefit people, especially patients. We feel that better diagnostics for diseases will enable people to take better preventative care and therapies.
Our ultimate goal is to bring together networks and consortia of genomic discovery researchers and link them to diagnostic bio-engineers so that improved diagnostics can be worked on. We do this by meeting genomic discovery groups at our events – groups that have discovery capabilities, relevant sample sets etc – and then we organize groups or consortia that can work together to achieve these goals. Sometimes we co-ordinate the projects ourselves and put the diagnostic workflows together too. The events help us meet the right kind of people and allow us to connect to them as well as connecting them to each other – this is why networking plays a key role in our events. As bioinformatics plays a big role in what we do, we try to keep abreast of developments and organize workshops in clinical bioinformatics with our partners such as Polyomics, Human Genetics Nijmegen or The Clinical Bioinformatics Company.
Finally we have been providing technical and commercial consulting to life science companies and university spin-outs for several years and this allows us to fund our events and workshops. Please feel free to contact us if you want to discuss any aspect of what you have read – if we can help we will and if not we have plenty of networks that very likely will.
Imagine an interactive conference where you hear the latest about genomic technologies, take part in workshops, debates, networking sessions with all the delegates! That’s a Biotexcel Conference.
Biotexcel organizes consortia for discovery to diagnostic workflow projects. Through our experience in consulting we have the resources to put together and coordinate workflows that are geared towards breaking the translational bottleneck and moving biomarkers into the clinic as diagnostic devices.
